Current Psychiatry Tardive Dyskinesia Articles
  • CME
  • CE

In the journal supplement to Current Psychiatry, diagnostic dilemmas and choosing the right treatment in patients with tardive dyskinesia (TD) were covered by Manish Jha, MBBS and Greg Mattingly, MD. These articles covered an overview of TD, identification of traditional treatment approaches to TD and their limitations, and details from recent research relating to the efficacy and safety of novel treatment options for TD.

To complete the evaluation and claim credit, please click “Begin Activity” at left and then “Claim Credit” on the next screen.

Manish Jha, MD
Greg Mattingly, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.5 Nursing contact hours
Pharmacists: 0.5 contact hours (0.05 CEUs)
Physician Assistants: maximum of 0.5 hours of AAPA Category I (Preapproved) credits
Released: October 29, 2021 Expiration: October 31, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss an overview of tardive TD
  • Identify the traditional treatment approaches for TD and understand their limitations
  • Recognize details from recent research relating to efficacy and safety of novel treatment options for TD

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant provided by
Neurocrine Biosciences

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Manish Jha, MD

Assistant Professor
Center for Depression Research and Clinical Care
Department of Psychiatry
UT Southwestern Medical Center
Dallas, Texas

Manish Jha, MBBS, has disclosed that he has received funds for research support from Acadia and Janssen R&D and consulting fees from Eleusis Therapeutics.
Greg Mattingly, MD

Associate Clinical Professor
Psychiatry, Psychopharmacology
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

Gregory Mattingly, MD, has disclosed that he has received consulting fees from AbbVie, Acadia, Alkermes, Axsome, Eisai, Ironshore, Intracellular, Janssen, Lundbeck, Neos, Neurocrine, Otsuka, Redax, Roche, Rhodes, Sage, Shire, Sunovion, Supernus, Takeda, Teva, and Trispharma; funds for research support from AbbVie, Acadia, Alkermes, Avanir, Axsome, Boehringer, Emalex, Janssen, Medgenics, NLS-1 Pharma AG, Redax, Roche, Sage, Shire, Sunovion, Supernus, Takeda, and Teva; and fees for non-CME/CE services from AbbVie, Alkermes, Eisai, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, and Trispharma.

Staff

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, NP, has no relevant conflicts of interest to report.
Mark Christiansen, PhD, PA-C
Mark Christiansen, PA-C, has no relevant conflicts of interest to report.
Laura Cobb, PhD
Laura Cobb, PhD, has no relevant conflicts of interest to report.
Lisa Phipps, PharmD, PhD
Lisa Phipps, PharmD, PhD, has no relevant conflicts of interest to report.
Prakash Masand, MD

Chief Medical Officer
Clinical Education Alliance
Adjunct Professor
Duke-NUS
New York, New York

Prakash Masand, MD, has disclosed that he has received consulting fees from AbbVie/Allergan, Acadia, Eisai, Intra-Cellular Therapies, Lundbeck, Sunovion, and Takeda; fees for non-CME services from AbbVie/Allergan, Intra-Cellular Therapies, Lundbeck, Sunovion, and Takeda; and funds for research support from AbbVie/Allergan.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists engaged in the care of patients with psychiatric illness.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to assess diagnostic considerations and new and emerging therapies for the treatment of psychiatric illness.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-175-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until October 31, 2022. PAs should only claim commensurate with the extent of their participation.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 29, 2021, through October 31, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Dr Greg Mattingly reviews the latest available clinical data for emerging diagnostic and therapy options for managing the mood disorders and TD, from Clinical Care Options (CCO)

Greg Mattingly, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: maximum of 1.0 hour of AAPA Category I CME credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: November 22, 2021 Expired: November 21, 2022

Clinical Care Options (CCO) commentary by Sanjay Gupta, MD, on choosing the right VMAT2 inhibitor for TD

Sanjay Gupta, MD Released: November 19, 2021

In this activity, a panel of Sanjay Gupta, MD reviews salient research studies of interest relevant to depression, schizophrenia, ADHD and substance abuse and provides clinical commentary

Sanjay Gupta, MD Released: November 18, 2021

Commentary by Manish Jha, MD, on weight gain and metabolic differences in agents used for bipolar depression, from Clinical Care Options (CCO)

Manish Jha, MD Released: November 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue